aTyr Pharma Management
Management criteria checks 3/4
aTyr Pharma's CEO is Sanjay Shukla, appointed in Nov 2017, has a tenure of 6.83 years. total yearly compensation is $1.30M, comprised of 43.2% salary and 56.8% bonuses, including company stock and options. directly owns 0.18% of the company’s shares, worth $241.69K. The average tenure of the management team and the board of directors is 5.8 years and 15 years respectively.
Key information
Sanjay Shukla
Chief executive officer
US$1.3m
Total compensation
| CEO salary percentage | 43.2% |
| CEO tenure | 6.8yrs |
| CEO ownership | 0.2% |
| Management average tenure | 5.8yrs |
| Board average tenure | 15yrs |
Recent management updates
Recent updates
aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point
Sep 09We Think aTyr Pharma (NASDAQ:ATYR) Needs To Drive Business Growth Carefully
Jul 13
We're Hopeful That aTyr Pharma (NASDAQ:LIFE) Will Use Its Cash Wisely
Feb 03Here's Why We're Not Too Worried About aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation
Oct 04Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation
May 06We're Keeping An Eye On aTyr Pharma's (NASDAQ:LIFE) Cash Burn Rate
Jan 04aTyr Pharma rises on U.S. patent for anti-neuropilin-2 monoclonal antibodies
Sep 29aTyr Pharma stock rises on FDA fast track status for efzofitimod for lung disease
Sep 13aTyr Pharma gains with FDA Fast Track status for lead asset
Aug 11We Think aTyr Pharma (NASDAQ:LIFE) Needs To Drive Business Growth Carefully
May 10Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?
Jan 24aTyr Pharma: Successful Proof Of Concept In Pulmonary Sarcoidosis
Dec 28aTyr Stock Is Buoyant On Highly-Promising Lung Disease Data - Wait For Hype To Die Down And Buy
Sep 24Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?
Sep 23Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?
May 22aTyr Pharma, Inc. (NASDAQ:LIFE) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
Mar 25Did You Miss aTyr Pharma's (NASDAQ:LIFE) Impressive 103% Share Price Gain?
Feb 09
aTyr Pharma, Kyorin concludes subject visits for early-stage ATYR1923 trial in Japan
Jan 14ATyr Pharma's lead candidate meets safety endpoint in COVID-19 study
Jan 04aTyr Pharma concludes enrollment in mid-stage inflammatory lung diseases study
Dec 21aTyr Pharma (LIFE) Investor Presentation - Slideshow
Oct 31CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$58m |
| Mar 31 2024 | n/a | n/a | -US$54m |
| Dec 31 2023 | US$1m | US$561k | -US$50m |
| Sep 30 2023 | n/a | n/a | -US$43m |
| Jun 30 2023 | n/a | n/a | -US$45m |
| Mar 31 2023 | n/a | n/a | -US$45m |
| Dec 31 2022 | US$2m | US$561k | -US$45m |
| Sep 30 2022 | n/a | n/a | -US$46m |
| Jun 30 2022 | n/a | n/a | -US$41m |
| Mar 31 2022 | n/a | n/a | -US$39m |
| Dec 31 2021 | US$2m | US$510k | -US$34m |
| Sep 30 2021 | n/a | n/a | -US$30m |
| Jun 30 2021 | n/a | n/a | -US$29m |
| Mar 31 2021 | n/a | n/a | -US$25m |
| Dec 31 2020 | US$1m | US$470k | -US$16m |
| Sep 30 2020 | n/a | n/a | -US$17m |
| Jun 30 2020 | n/a | n/a | -US$16m |
| Mar 31 2020 | n/a | n/a | -US$16m |
| Dec 31 2019 | US$664k | US$450k | -US$24m |
| Sep 30 2019 | n/a | n/a | -US$24m |
| Jun 30 2019 | n/a | n/a | -US$25m |
| Mar 31 2019 | n/a | n/a | -US$30m |
| Dec 31 2018 | US$1m | US$450k | -US$35m |
| Sep 30 2018 | n/a | n/a | -US$40m |
| Jun 30 2018 | n/a | n/a | -US$44m |
| Mar 31 2018 | n/a | n/a | -US$45m |
| Dec 31 2017 | US$2m | US$403k | -US$48m |
Compensation vs Market: Sanjay's total compensation ($USD1.30M) is above average for companies of similar size in the US market ($USD677.23K).
Compensation vs Earnings: Sanjay's compensation has been consistent with company performance over the past year.
CEO
Sanjay Shukla (52 yo)
6.8yrs
Tenure
US$1,300,525
Compensation
Dr. Sanjay S. Shukla, M.D. M.S. has been the Chief Executive Officer, President and Director at aTyr Pharma, Inc. since November 1, 2017. Dr. Shukla served as Chief Medical Officer at aTyr Pharma, Inc. fro...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.8yrs | US$1.30m | 0.18% $ 241.7k | |
| Chief Financial Officer | 6.2yrs | US$677.84k | 0.027% $ 36.9k | |
| General Counsel & Corporate Secretary | 9.9yrs | US$651.28k | 0.029% $ 39.4k | |
| Founder | no data | no data | no data | |
| Vice President of Technical Operations | less than a year | no data | no data | |
| Director of Investor Relations & Corporate Communications | no data | no data | no data | |
| Vice President of Corporate Development | 4.7yrs | no data | no data | |
| VP of Human Resource | 2.8yrs | no data | no data | |
| Vice President of Research | no data | no data | no data | |
| Executive Director of Biologics Development & Manufacturing | no data | no data | no data | |
| Scientific Consultant | 5.8yrs | US$717.31k | no data |
5.8yrs
Average Tenure
62yo
Average Age
Experienced Management: ATYR's management team is seasoned and experienced (5.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.8yrs | US$1.30m | 0.18% $ 241.7k | |
| Independent Director | 19yrs | US$120.84k | 0.026% $ 35.0k | |
| Independent Director | 19yrs | US$61.20k | 1.45% $ 1.9m | |
| Member of Scientific Advisory Board | 14.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 15.1yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Chairman of the Board | 7.4yrs | US$92.20k | 0.074% $ 99.1k | |
| Member of Scientific Advisory Board | 15yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 5.2yrs | US$68.88k | 0.0079% $ 10.6k |
15.0yrs
Average Tenure
67yo
Average Age
Experienced Board: ATYR's board of directors are seasoned and experienced ( 15 years average tenure).